Related Experiment Videos

[Pharmacogenetics and anti-inflammatory effect of HMG-CoA reductase inhibitors]

Alexandre B Rosendo1, Felipe Dal-Pizzol, Marilu Fiegenbaum

  • 1Laboratório de Fisiopatologia Experimental, Universidade do Extremo Sul Catarinense, Criciúma, SC.

Arquivos Brasileiros De Endocrinologia E Metabologia
|August 9, 2007
PubMed

Insights

Statins reduce atherosclerosis-related inflammation, indicated by lower C-reactive protein levels. Genetic variations may influence both the lipid-lowering and anti-inflammatory effects of statins.

Area of Science:

  • Cardiovascular Medicine
  • Immunology
  • Pharmacogenetics

Context:

  • Atherosclerosis involves arterial wall lipid deposition and inflammation.
  • Systemic inflammation markers like C-reactive protein (CRP) correlate with cardiovascular risk.
  • Statins decrease atherosclerosis-related inflammation, evidenced by reduced CRP levels.

Purpose:

  • To explore the relationship between genetic variations and the anti-inflammatory effects of statins.
  • To investigate how genetic factors influence statins' impact on immune function and protein prenylation.

Summary:

  • Atherosclerosis is linked to inflammation, detectable by C-reactive protein (CRP).
  • Statins reduce this inflammation, a process potentially involving modulation of protein prenylation.
  • While genetic variations affect statins' lipid-lowering effects, their influence on anti-inflammatory actions is less studied.

Impact:

  • Highlights the potential role of pharmacogenetics in understanding statin efficacy beyond lipid reduction.
  • Suggests genetic factors influencing statin pharmacodynamics/pharmacokinetics may also mediate anti-inflammatory outcomes.
  • Underscores the need for further research into genetic determinants of statin's pleiotropic effects.

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu01:29

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...
Drug toxicity: Idiosyncratic Reactions01:16

Drug toxicity: Idiosyncratic Reactions

Idiosyncratic drug reactions represent abnormal chemical responses that vary significantly among individuals, ranging from extreme sensitivity to low doses to insensitivity to high doses. These reactions often occur due to the drug's covalent binding with serum proteins, forming a foreign hapten that triggers an immunotoxicological response. The variability in drug reactions has a strong pharmacogenetic foundation, with genetic differences crucial in how individuals metabolize drugs. For...
Pharmacogenetics of Drug Metabolism: Overview01:27

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...